ConductScience.org, home

Paper41007643

Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier.

Tiwari A and 9 others. Biomedicines, 2025. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier. Papers, record 41007643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41007643

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier.
PubMed
Journal
Biomedicines
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
2.1, provisional
iCite
Revised in PubMed
2025-09-30
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tiwari AAngadhttps://orcid.org/0009-0002-9018-8328
2Sharma AAshish
3Kumar HHarendrahttps://orcid.org/0000-0001-6801-0633
4Gupta VVarnikahttps://orcid.org/0009-0005-7605-8799
5Deshpande VVishalhttps://orcid.org/0009-0005-5652-8650
6Mupparaju JSJaya Saihttps://orcid.org/0009-0000-1368-8455
7Mishra TTanisha
8Bharadwaj HRHareesha Rishabhttps://orcid.org/0000-0002-7979-2834
9Dahiya DSDushyant Singhhttps://orcid.org/0000-0002-8544-9039
10Jain VVarunhttps://orcid.org/0009-0004-4243-2925

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References67

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139558940Resmetirom.Hosp Pharm2025https://conductscience.org/library/papers/39558940PubMed
239621874Safety and efficacy of resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): a systematic review and meta-analysis.Eur J Gastroenterol Hepatol2025https://conductscience.org/library/papers/39621874PubMed
337845512Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.Nat Med2023https://conductscience.org/library/papers/37845512PubMed
439420154Actions of thyroid hormones and thyromimetics on the liver.Nat Rev Gastroenterol Hepatol2025https://conductscience.org/library/papers/39420154PubMed
533185364A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.N Engl J Med2021https://conductscience.org/library/papers/33185364PubMed
621990298Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).JAMA2011https://conductscience.org/library/papers/21990298PubMed
739150005Vitamin E improves serum markers and histology in adults with metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis.J Gastroenterol Hepatol2024https://conductscience.org/library/papers/39150005PubMed
828670712Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment.J Gastroenterol Hepatol2018https://conductscience.org/library/papers/28670712PubMed
922297845Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.Nature2012https://conductscience.org/library/papers/22297845PubMed
1039126031NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.Int J Mol Sci2024https://conductscience.org/library/papers/39126031PubMed
1136910628Potential use of TG68 - A novel thyromimetic - for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis.Front Oncol2023https://conductscience.org/library/papers/36910628PubMed
1238851997EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).J Hepatol2024https://conductscience.org/library/papers/38851997PubMed
1324075770Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist.Atherosclerosis2013https://conductscience.org/library/papers/24075770PubMed
1439187533
Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.
Sci Rep2024https://conductscience.org/library/papers/39187533PubMed
1524712661
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia.
J Med Chem2014https://conductscience.org/library/papers/24712661PubMed
1626549695Obeticholic acid for the treatment of primary biliary cirrhosis.Expert Rev Clin Pharmacol2016https://conductscience.org/library/papers/26549695PubMed
1736626630The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.Hepatology2023https://conductscience.org/library/papers/36626630PubMed
1830300287Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.Transplantation2019https://conductscience.org/library/papers/30300287PubMed
1912888625Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability.Proc Natl Acad Sci U S A2003https://conductscience.org/library/papers/12888625PubMed
2037786277Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis.Aliment Pharmacol Ther2024https://conductscience.org/library/papers/37786277PubMed

See all 67 referencesDownload CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42883860Canonical and Non-Canonical Regulators of Lipid Metabolism in the Liver and the "Liver-Other Organs" Axes.Int J Mol Sci2026https://conductscience.org/library/papers/42883860PubMed
42864313Hydrogen peroxide sensing and signaling in physiology and disease: implications for therapy.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42864313PubMed
42796348Cardiovascular-Kidney-Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review.Medicina (Kaunas)2026https://conductscience.org/library/papers/42796348PubMed
42706950From targeted drug delivery to tissue regeneration: the evolving role of nanoparticle therapies in liver disease.Regen Med2026https://conductscience.org/library/papers/42706950PubMed
42666480Metabolic dysfunction-associated steatotic liver disease as a systemic disorder: extrahepatic manifestations and the need for data-driven phenotyping.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42666480PubMed
42612975Targeting microbial bile salt hydrolase reprograms bile acid metabolism and ameliorates metabolic dysfunction-associated steatohepatitis in mice.Mol Metab2026https://conductscience.org/library/papers/42612975PubMed
42496289FDA-Approved Drugs Containing Amide Functionality in the Last Five Years (2021-2025): Pharmaceutical Use, Trends and Synthetic Approaches.Medicines (Basel)2026https://conductscience.org/library/papers/42496289PubMed
42182451Targeting Microbial Bile Salt Hydrolase Reprograms Bile Acid Metabolism and Ameliorates Metabolic Dysfunction-Associated Steatohepatitis in Mice.bioRxiv2026https://conductscience.org/library/papers/42182451PubMed
41983208Dapagliflozin for metabolic dysfunction-associated steatohepatitis with fibrosis: a promising therapeutic agent in biopsy-diagnosed patients.Hepatobiliary Surg Nutr2026https://conductscience.org/library/papers/41983208PubMed
41617025HIF-2α induction in de novo lipogenesis in metabolic dysfunction-associated steatohepatitis is dependent on IL-21 signaling.J Biol Chem2026https://conductscience.org/library/papers/41617025PubMed
41595685The Role of Kupffer Cells and Liver Macrophages in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease.Biomedicines2026https://conductscience.org/library/papers/41595685PubMed
41463398Insulin Resistance at the Crossroads of Metabolic Inflammation, Cardiovascular Disease, Organ Failure and Cancer.Biomolecules2025https://conductscience.org/library/papers/41463398PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41007643

GET https://conductscience.org/api/papers/v1/41007643/references?page=2